<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89460">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940497</url>
  </required_header>
  <id_info>
    <org_study_id>ML28879</org_study_id>
    <secondary_id>2013-001161-16</secondary_id>
    <nct_id>NCT01940497</nct_id>
  </id_info>
  <brief_title>SCHEARLY Study: A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This non-randomized, multicenter, open-label study will assess the safety and efficacy of
      subcutaneously administered trastuzumab in participants with early and locally advanced
      HER2-positive breast cancer in two sequential cohorts. First 120 participants will be
      treated with subcutaneous (SC) trastuzumab (600 milligrams per 5 milliliter [mg/5mL] vial
      (Cohort A) and the subsequent 120 participants will be treated with SC trastuzumab prefilled
      single use injection device (SID) (Cohort B). Participants from each cohort will receive
      neo-adjuvant or adjuvant chemotherapy consisting of 4 cycles of anthracyclines followed by 4
      cycles of paclitaxel weekly or docetaxel every 3 weeks (q3w) in combination with SC
      trastuzumab (600 milligrams [mg]) q3w and a further 14 cycles of SC trastuzumab (600 mg) q3w
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Exposure to Trastuzumab Treatment</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Trastuzumab Treatment</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Received Concomitant Medications</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pathological Complete Response (in the Neo-Adjuvant Setting)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>up to approximately 4.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to approximately 4.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Satisfied With Use of Trastuzumab SC SID Assessed by Patient Satisfaction Questionnaire</measure>
    <time_frame>63 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Health Care Professionals Who Satisfied With Trastuzumab SC SID Assessed by Health Care Professional Questionnaire</measure>
    <time_frame>63 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A: Trastuzumab SC Vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in 2 sequential cohorts will be treated with SC trastuzumab 600 mg solution. Participants from each cohort will receive neo-adjuvant or adjuvant chemotherapy consisting of 4 cycles of anthracyclines (doxorubicin) followed by 4 cycles of paclitaxel weekly or docetaxel q3w in combination with SC trastuzumab (600 mg) q3w and a further 14 cycles of SC trastuzumab (600 mg) q3w alone, using a conventional syringe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Trastuzumab SC SID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in 2 sequential cohorts will be treated with SC trastuzumab 600 mg prefilled SID. Participants from each cohort will receive neo-adjuvant or adjuvant chemotherapy consisting of 4 cycles of anthracyclines (doxorubicin) followed by 4 cycles of paclitaxel weekly or docetaxel q3w in combination with SC trastuzumab (600 mg) q3w and a further 14 cycles of SC trastuzumab (600 mg) q3w alone, prefilled SID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Participants will receive doxorubicin (60 milligrams per meter square [mg/m^2]) q3w, 4 cycles prior to initiation of trastuzumab treatment.</description>
    <arm_group_label>Cohort A: Trastuzumab SC Vial</arm_group_label>
    <arm_group_label>Cohort B: Trastuzumab SC SID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxane: Docetaxel</intervention_name>
    <description>Participants will receive docetaxel q3w for 12 weeks, in combination with trastuzumab.</description>
    <arm_group_label>Cohort A: Trastuzumab SC Vial</arm_group_label>
    <arm_group_label>Cohort B: Trastuzumab SC SID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxane: Paclitaxel</intervention_name>
    <description>Participants will receive paclitaxel weekly for 12 weeks, in combination with trastuzumab.</description>
    <arm_group_label>Cohort A: Trastuzumab SC Vial</arm_group_label>
    <arm_group_label>Cohort B: Trastuzumab SC SID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Participants will receive 600 mg SC (vial or single-use injection device) q3w for 18 cycles.</description>
    <arm_group_label>Cohort A: Trastuzumab SC Vial</arm_group_label>
    <arm_group_label>Cohort B: Trastuzumab SC SID</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-metastatic primary invasive adenocarcinoma of the
             breast. Stage of disease: T1-4 (T describes size of tumour from 1 to 4), N0-3 (N
             describes nearby lymph nodes), M0 (M describes distant metastasis)

          -  HER2-positive disease immunohistochemistry (IHC) 3+ or in situ hybridization (ISH)
             positive

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Left ventricular ejection fraction (LVEF) of greater than or equal to (&gt;/=) 55
             percent (%) measured by echocardiography (ECHO) or multiple gated acquisition (MUGA)
             scan prior to first dose of trastuzumab SC

          -  Intact skin at site of SC injection on the thigh

        Exclusion Criteria:

          -  History of other malignancy, except for participants with curatively treated
             carcinoma in situ of the cervix or basal cell carcinoma and participants with other
             curatively treated malignancies, other than breast cancer, who have been disease-free
             for at least 5 years

          -  Severe dyspnea at rest or requiring supplementary oxygen therapy

          -  Concurrent serious diseases that may interfere with planned treatment, including
             severe pulmonary conditions/illness

          -  Serious cardiac illness or medical conditions that would preclude the use of
             trastuzumab, specifically: history of documented congestive heart failure (CHF),
             high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically
             significant valvular disease, evidence of transmural infarction on electrocardiogram
             (ECG), diagnosed poorly controlled hypertension

          -  Known infection with human immunodeficiency virus (HIV), active hepatitis B virus
             (HBV) or hepatitis C virus (HCV)

          -  Pregnant or lactating women

          -  Concurrent enrolment in another clinical trial using an investigational anti-cancer
             treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy,
             within 28 days prior to the first dose of study treatment

          -  Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of
             Herceptin including hyaluronidase, or the adhesive of the SC device (for cohort B),
             or a history of severe allergic or immunological reactions, e.g. difficulty to
             control asthma

          -  Inadequate bone marrow, hepatic or renal function

          -  Hormonal treatment concomitant with chemotherapy (allowed in adjuvant phase with
             adjuvant trastuzumab SC)

          -  Pre-existing motor or sensory neuropathy of Grade greater than (&gt;) 1

          -  Sincronous bilateral invasive breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>L'aquila</city>
        <state>Abruzzo</state>
        <zip>67010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potenza</city>
        <state>Basilicata</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Calabria</city>
        <state>Calabria</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frattamaggiore</city>
        <state>Campania</state>
        <zip>80027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carpi</city>
        <state>Emilia-Romagna</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guastalla</city>
        <state>Emilia-Romagna</state>
        <zip>42016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aviano</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Spezia</city>
        <state>Liguria</state>
        <zip>19125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alzano Lombardo</city>
        <state>Lombardia</state>
        <zip>24022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Como</city>
        <state>Lombardia</state>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecco</city>
        <state>Lombardia</state>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mantova</city>
        <state>Lombardia</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saronno</city>
        <state>Lombardia</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviglio</city>
        <state>Lombardia</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <state>Lombardia</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macerata</city>
        <state>Marche</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pesaro</city>
        <state>Marche</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asti</city>
        <state>Piemonte</state>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Candiolo</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponderano (BI)</city>
        <state>Piemonte</state>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grosseto</city>
        <state>Toscana</state>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lido Di Camaiore</city>
        <state>Toscana</state>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livorno</city>
        <state>Toscana</state>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poggibonsi</city>
        <state>Toscana</state>
        <zip>53036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Veneto</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mestre</city>
        <state>Veneto</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mirano</city>
        <state>Veneto</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Negrar</city>
        <state>Veneto</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
